THX Pharma Société Anonyme (EPA:ALTHX)

Market Cap	42.08M +1,146.8%
Revenue (ttm)	876.13K -61.3%
Net Income	-2.94M
EPS	-0.31
Shares Out	13.80M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,196
Average Volume	90,575
Open	3.080
Previous Close	3.150
Day's Range	3.020 - 3.080
52-Week Range	0.261 - 5.100
Beta	1.54
RSI	49.84
Earnings Date	Apr 28, 2026

About EPA:ALTHX

THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonyme in September 2025. The company was founded in 2013 and is headquartered in Lyon, France.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 10
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTHX

Financial Performance

In 2024, EPA:ALTHX's revenue was 2.28 million, an increase of 670.55% compared to the previous year's 296,331. Losses were -1.77 million, -74.15% less than in 2023.